- RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
This study is testing a new medicine, sonrotoclax, for people in the UK with multiple myeloma that has come back or isn't responding to treatment. Researchers want to see how safe and effective it is, both on its own and with other common myeloma drugs.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
For: CLLUnited States · Australia · Austria - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
This study is looking at a new combination of medicines, sonrotoclax plus zanubrutinib, for adults in the UK with a type of blood cancer called Mantle Cell Lymphoma. It aims to see if this combination works better and is safe when their cancer has come back or isn't responding to other treatments.
For: Mantle Cell Lymphoma · B Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE2
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation
This study is looking at new drug combinations for a type of blood cancer called Richter Transformation. It aims to see if two existing drugs, zanubrutinib and tislelizumab, with or without a new drug, sonrotoclax, can safely and effectively treat patients aged 18 and over.
For: Richter TransformationAustria · Denmark · Germany - RecruitingPHASE1, PHASE2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
This study looks at new ways to give a medicine called sonrotoclax for blood cancers like Chronic Lymphocytic Leukemia (CLL). We want to find the safest and most effective starting dose schedule, often with another medicine called zanubrutinib, to help patients.
For: Chronic Lymphocytic Leukemia · CLL · Mantle Cell LymphomaUnited States · Australia · France - Active not recruitingPHASE1
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
This study is testing a new medicine called sonrotoclax for certain blood cancers like lymphoma and leukaemia. We want to find the safest and most effective dose, both on its own and when combined with other medicines, to help patients with these conditions.
For: Mature B-Cell MalignanciesUnited States · Australia · Germany - RecruitingPHASE1, PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
This study looks at a new drug, BGB-16673, combined with other medicines for people with B-cell cancers that have come back or not responded to past treatments. It checks how safe and effective these combinations are.
For: B-cell Malignancy · Relapsed Cancer · Refractory CancerUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
This study looks at a new drug, Sonrotoclax, for adults with Waldenström Macroglobulinemia. It tests the drug alone for those whose previous treatments weren't enough, and with another drug, Zanubrutinib, for those who haven't had treatment before. The aim is to see if it's safe and effective.
For: Waldenstrom Macroglobulinemia · Waldenstrom's Macroglobulinemia Recurrent · Waldenstrom's Macroglobulinemia RefractoryUnited States · Australia · Canada